Dialysis-related amyloidosis: Pathogenesis focusing on AGE modification

Seminars in Dialysis

Volumn 14, Issue 2, 2001, Pages 123-126

  Niwa, Toshimitsu ^a  

^a NAGOYA UNIVERSITY HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; AMYLOID; COLLAGEN;

AMYLOIDOSIS; HEART MUSCLE; HUMAN; MACROPHAGE; METABOLISM; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; UREMIA; VERTEBRAL CANAL STENOSIS;

AMYLOID; AMYLOIDOSIS; COLLAGEN; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MACROPHAGES; MYOCARDIUM; RENAL DIALYSIS; RISK FACTORS; SPINAL STENOSIS; UREMIA;

EID: 0035291226     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-139x.2001.00031.x     Document Type: Article

References (12)

1. 2-microglobulin dialysis amyloid and its formation: role of 3-deoxyglucosone and advanced glycation end products. Nephron 76:373-391, 1997
2. Nokura K, Koga H, Yamamoto H, Kimura A, Tamai H, Yazaki S, Suzuki N, Miyazaki S, Niwa T: Dialysis-related spinal canal stenosis: a clinicopathological study on amyloid deposition and its AGE modification. J Neurol Sci 178:114-123, 2000
3. Takayama F, Aoyama I, Tsukushi S, Miyazaki T, Miyazaki S, Morita T, Hirasawa Y, Shimokata K, Niwa T: Dialysis-related amyloidosis of the heart in long-term hemodialysis patients: Localization of advanced glycation end products and calcification. Kidney Int (in press)
4. 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. J Clin Invest 92:1243-1252, 1993
5. 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 93:521-528, 1994
6. Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 93:2353-2358, 1996
7. 2M amyloid fibril extension in vitro. Amyloid 6:256-264, 1999
8. Niwa T, Katsuzaki T, Miyazaki S, Momoi T, Akiba T, Miyazaki T, Nokura K, Hayase F, Tatemichi N, Takei Y: Amyloid β2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Kidney Int 51:187-194, 1997
9. Niwa T, Katsuzaki T, Miyazaki S, Miyazaki T, Ishizaki Y, Hayase F, Tatemichi N, Takei Y: Immunohistochemical detection of imidazolone, a novel advanced glycation end product, in kidneys and aortas of diabetic patients. J Clin Invest 99:1272-1280, 1997
10. Niwa T, Sato M, Katsuzaki T, Tomoo T, Miyazaki T, Tatemichi N, Takei Y, Kondo T: Amyloid β2-microglobulin is modified with Nε-(carboxymelhyl) lysine in dialysis-related amyloidosis. Kidney Int 50:1303-1309, 1996
11. Niwa T, Miyazaki S, Katsuzaki T, Tatemichi N, Takei Y, Miyazaki T, Morita T, Hirasawa Y: Immunohistochemical detection of advanced glycation end products in dialysis-related amyloidosis. Kidney Int 48:771-778, 1995
12. Niwa T, Takeda N, Miyazaki T, Yoshizumi H, Tatematsu A, Maeda K, Ohara M, Tomiyama S, Niimura K: Elevated serum levels of 3-deoxyglucosone, a potent protein-cross-linking intermediate of the Maillard reaction, in uremic patients. Nephron 69:438-443, 1995